leadf
logo-loader
viewCo-Diagnostics

Co-Diagnostics appoints long-time executive Brian Brown as its new chief financial officer

Brown's previous experience includes CFO, vice president of accounting and investor relations, and director of finance roles for public and private companies

Co-Diagnostics - Co-Diagnostics Inc appoints long-time executive Brian Brown as its new chief financial officer
Co-Diagnostics said it has also elevated Dr Jesse Montgomery, its senior vice president of biochemistry, to the post of chief scientific officer 

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company’s new chief financial officer (CFO).

The company said Brown's previous experience includes CFO, vice president of accounting and investor relations, and director of finance roles for public and private companies. 

In a statement, Brown called Co-Diagnostics a “true success story,” adding that “I was immediately drawn to the Company's vision and ability to run a profitable, well-managed operation during a period of dynamic growth. I look forward to bringing my experience to support the Company in these endeavors."

The Utah-based company also said it has elevated Dr Jesse Montgomery to the post of chief scientific officer. Dr Montgomery has been the company's senior vice president of biochemistry, following a career that has included research and bioinformatics positions.

READ: Co-Diagnostics completes FDA submission for Emergency Use Authorization for its Logix Smart SARS-CoV-2 DS (Direct Saliva) test

In addition, the company said that former CFO Reed Benson will remain with it as general counsel, and Dr Brent Satterfield, founder and former CSO, will continue his involvement with Co-Diagnostics as head of the scientific advisory board.

“It has been my pleasure to serve as CSO for Co-Diagnostics,” said Dr Satterfield. “In my new capacity as Head of the Scientific Advisory Board, I look forward to exploring new, innovative ways to further strengthen our scientific base, and advancing our ongoing goal of meeting global health challenges by providing affordable, state-of-the-art diagnostic solutions to the world community."

Dr Montgomery added: "Our Company vision, technology platform, and experience are some of our greatest assets, which combined with the groundwork laid by Dr. Satterfield's vision have all primed the Company for success. I am excited to oversee the Company's current and future scientific endeavors as Co-Diagnostics continues to progress and innovate in the field of molecular diagnostics."

The personnel changes follow significant growth Bu Co-Diagnostics in the past year and as the company anticipates additional growth going forward. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Co-Diagnostics

Price: 15.4 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $435.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read